ACE inhibitors are linked to increased lung cancer risk, study finds
BMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4471 (Published 24 October 2018) Cite this as: BMJ 2018;363:k4471Linked research
Angiotensin converting enzyme inhibitors and risk of lung cancer
- Zosia Kmietowicz
- The BMJ
Angiotensin converting enzyme inhibitors (ACEIs) are associated with a higher risk of lung cancer than angiotensin receptor blockers (ARBs), especially if used for more than five years, a study in The BMJ has found.1
Although the risk to individual patients is modest, the absolute numbers of patients at risk for lung cancer is potentially large because ACEIs are widely prescribed, said the researchers.
Evidence suggests that ACEIs increase the risk of lung cancer through the build-up of bradykinin and substance P …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.